Hot Features
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's le... Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.4 | -10.3092783505 | 3.88 | 3.9 | 3.4 | 863974 | 3.62960689 | CS |
| 4 | -0.39 | -10.0775193798 | 3.87 | 4.14 | 3.4 | 1034941 | 3.79639553 | CS |
| 12 | 0.72 | 26.0869565217 | 2.76 | 4.2 | 2.655 | 1369426 | 3.48312322 | CS |
| 26 | 1.87 | 116.149068323 | 1.61 | 4.2 | 1.44 | 1087697 | 2.91453472 | CS |
| 52 | 0.45 | 14.8514851485 | 3.03 | 4.6 | 1.35 | 1274608 | 2.73452818 | CS |
| 156 | 1.55 | 80.310880829 | 1.93 | 5.54 | 1.07 | 551576 | 2.86074456 | CS |
| 260 | -5.73 | -62.2149837134 | 9.21 | 9.435 | 1.07 | 358345 | 2.94484133 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.